Results 151 to 160 of about 26,261 (211)

Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early‐Phase Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The management of the disease of obesity has been transformed by incretin‐based therapies; however, additional and alternative therapeutic strategies are needed to address its biological complexity. This narrative review examines the physiology of amylin and the emerging role of amylin‐based therapies in obesity management.
Abdulhameed Alhazmi, Carel W. le Roux
wiley   +1 more source

Association of Glucagon-like Peptide-1 Receptor Agonist Use with Stroke and Mortality Outcomes in Asymptomatic Intracranial Atherosclerotic Disease: Propensity Score-Matched Real-World Analysis. [PDF]

Neurol Int
Rai P, Mandel D, Bathla G, Dhaduk V, Rajeev R, Kakadiya J, Chen HA, Salim HA, Azzam AY, Essibayi MA, Connolly B, Buzzelli M, Yedavalli VS, Khan M, Dmytriw AA, Altschul DJ, McIntyre MK, Colasurdo M, Malhotra A, Gandhi D, Lakhani DA.   +20 more
europepmc   +1 more source

Early Weight Regain After GLP‐1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De‐Escalation Strategies

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have transformed the pharmacological management of obesity, producing substantial and sustained weight loss during active treatment. However, discontinuation of therapy is frequently followed by significant weight regain, raising important questions regarding the durability of treatment ...
M. A. Damhof, F. H. van Bruggen, E. N. van Roon   +2 more
wiley   +1 more source

Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)—An International Phase 3 Clinical Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Attaining target glycaemia can be a challenge in Type 1 Diabetes (T1D) due to insulin‐induced weight gain. Adjunct therapy with modern glucose‐lowering agents developed for type 2 diabetes (T2D) has great potential but may be insufficiently efficacious and carries risks of hypoglycaemia and ketosis.
Joseph G. Timmons, Husam Ghanim, James G. Boyle, Nicola Greenlaw, Ajay Chaudhuri, Manav A. Batra, Robert S. Lindsay, Lisa Jolly, Caroline Bonner, Alex McConnachie, John R. Petrie, Paresh Dandona   +11 more
wiley   +1 more source

Suspected liraglutide (glucagon-like peptide-1 receptor agonist)-induced hyperthyroidism: A case report. [PDF]

Malays Fam Physician
Md Sabudin SNS, Yaacob LH, Che Omar MR.
europepmc   +1 more source

Durability and Safety of Imeglimin as an Add‐On to DPP‐4 Inhibitors in Japanese Type 2 Diabetes: The 104‐Week FAMILIAR Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the long‐term efficacy and safety of imeglimin added to dipeptidyl peptidase‐4 (DPP‐4) inhibitors in Japanese patients with type 2 diabetes, focusing on glycemic durability and safety in elderly patients over 104 weeks. Materials and Methods This multicenter, randomized, placebo‐controlled trial comprised a 24‐week double ...
Masashi Shimoda, Takeshi Osonoi, Masahiro Iwamoto, Hideaki Kaneto, Kohei Kaku   +4 more
wiley   +1 more source

Super effect or methodological flaw: questioning the glucagon-like peptide-1 receptor agonist cancer narrative. [PDF]

Diabetologia
Maier GA, Rathmann W, Kuß O.
europepmc   +1 more source

Molecular Characterization of the Effect of Glucagon-Like Peptide-1 Receptor Agonist Semaglutide in the Nephrotoxic Serum Nephritis Mouse Model. [PDF]

Kidney360
Martinez JM, Ougaard M, Grancharova T, Zdravkovic RD, Østergaard MV, Bénardeau A, Knudsen LB, Pyke C, Kvist PH, Hvid H.   +9 more
europepmc   +1 more source

The Upfront Effectiveness of a 6‐Week Continuous Glucose Monitoring Intervention for Non‐Insulin‐Using Individuals With Type 2 Diabetes Is No Longer Detectable at 6–12 Months: An Observational Follow‐Up of a Randomized Trial Cohort

Diabetes, Obesity and Metabolism, EarlyView.
Jiawei Ryan Zhang, Roseanne O. Yeung, Donna P. Manca, Pratima Singh, Inga Olu‐Jordan, Tawnya Perry, Gulelala Rahim, Evan M. Hagen, Darren Lau   +8 more
wiley   +1 more source

Glucagon-like peptide 1 receptor agonist discontinuation and risks of major adverse cardiovascular events in adults with type 2 diabetes: target trial emulation. [PDF]

BMJ Med
Xie Y, Choi T, Al-Aly Z.
europepmc   +1 more source